[ad_1]
South Africa has obtained a significant discount for the first new drug in 60 years to treat multidrug-resistant tuberculosis.
The cost has been reduced from 10,000 to 5,400 rand for treatment. [19659002] The drug bedaquiline, manufactured by Janssen, a division of Johnson & Johnson, was a major breakthrough because it replaces a painful multi-resistant injectable antituberculous drug that causes deafness in 60% of patients.
would have months of extremely painful injections to eventually be cured of deadly tuberculosis to eventually become deaf.
South Africa has the highest number of multiresistance cases in the world with more than 15,000 people
In South Africa, multidrug-resistant tuberculosis has a very low cure rate (less than 40 % of patients treated) and those who suffer from it can not take drugs against tuberculosis. infectious, deadly disease spread furt
Last week, Section 27 demanded that the price of bedaquiline, also called Sirturo, be lowered to allow more patients to get the drug, which must be taken with two other antibiotics.
Bedaquiline also has more treatment According to a new essay based on South African data, published in the prestigious journal The Lancet
[ad_2]
Source link
